{"id":"W2746091303","doi":"10.1200/jco.2017.73.0226","title":"Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Thyroid Cancer Diagnosis and Treatment","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"ca_institutions":"Amgen (Canada)","funders":"National Cancer Institute","keywords":"Medicine; Cabozantinib; Lenvatinib; Pazopanib; Sorafenib; Internal medicine; Response Evaluation Criteria in Solid Tumors; Medullary thyroid cancer; Oncology; Thyroid cancer; Sunitinib; Refractory (planetary science); Tyrosine-kinase inhibitor; Adverse effect; Population; Axitinib; Cancer; Clinical trial; Phases of clinical research; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001967672,0.001343237,0.001858737,0.0002980286,0.000442908,0.0008605078,0.0006786893,0.001029758,0.001276929],"category_scores_gemma":[0.001076178,0.0003260414,0.001320095,0.0003366993,0.0006484499,0.0005019177,0.0001989335,0.001749809,0.0003266257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001318018,"about_ca_system_score_gemma":0.001523965,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00194096,"about_ca_topic_score_gemma":0.004460299,"domain_scores_codex":[0.9995087,0.0002439837,0.00003101378,0.00008406855,0.00004404244,0.0000881567],"domain_scores_gemma":[0.9992518,0.0001107004,0.0001371307,0.00005129647,0.00004797727,0.0004011304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8266431,0.02241099,0.01530666,0.0006736974,0.002239598,0.0004734887,0.0003806244,0.001846799,0.02265958,0.0001887529,0.005416763,0.1017599],"study_design_scores_gemma":[0.7202344,0.2319683,0.03664609,0.00007069917,0.001674062,0.0005027909,0.0001158914,0.002018375,0.002449805,0.000192954,0.004079932,0.00004666427],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901723,0.006001272,0.0002772021,0.0006080998,0.0001330929,0.0008948881,0.0007638439,0.00005673751,0.001092482],"genre_scores_gemma":[0.9920197,0.00267556,0.0007584315,0.0008514175,0.0002528451,0.000756097,0.001909909,0.00001602714,0.0007599494],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001967672,"threshold_uncertainty_score":0.01040614,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07839486005662127,"score_gpt":0.4642816191764927,"score_spread":0.3858867591198714,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}